Cargando…
HIV takes double hit before entry
In the absence of a vaccine or a cure, identification of novel HIV-1 inhibitors remains important. A paper in Retrovirology describes a rationally designed bi-specific protein that irreversibly damages the viral envelope glycoprotein complex via a two-punch mechanism. In contrast to traditional drug...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517473/ https://www.ncbi.nlm.nih.gov/pubmed/23216951 http://dx.doi.org/10.1186/1741-7007-10-99 |
_version_ | 1782252419347906560 |
---|---|
author | Sanders, Rogier W |
author_facet | Sanders, Rogier W |
author_sort | Sanders, Rogier W |
collection | PubMed |
description | In the absence of a vaccine or a cure, identification of novel HIV-1 inhibitors remains important. A paper in Retrovirology describes a rationally designed bi-specific protein that irreversibly damages the viral envelope glycoprotein complex via a two-punch mechanism. In contrast to traditional drugs that inhibit essential steps in the viral life cycle at the cell surface or in the infected cells, this inhibitor cripples free virus in the absence of cells. See research article: http://www.retrovirology.com/content/9/1/104 |
format | Online Article Text |
id | pubmed-3517473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35174732012-12-19 HIV takes double hit before entry Sanders, Rogier W BMC Biol Commentary In the absence of a vaccine or a cure, identification of novel HIV-1 inhibitors remains important. A paper in Retrovirology describes a rationally designed bi-specific protein that irreversibly damages the viral envelope glycoprotein complex via a two-punch mechanism. In contrast to traditional drugs that inhibit essential steps in the viral life cycle at the cell surface or in the infected cells, this inhibitor cripples free virus in the absence of cells. See research article: http://www.retrovirology.com/content/9/1/104 BioMed Central 2012-12-07 /pmc/articles/PMC3517473/ /pubmed/23216951 http://dx.doi.org/10.1186/1741-7007-10-99 Text en Copyright ©2012 Sanders; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary Sanders, Rogier W HIV takes double hit before entry |
title | HIV takes double hit before entry |
title_full | HIV takes double hit before entry |
title_fullStr | HIV takes double hit before entry |
title_full_unstemmed | HIV takes double hit before entry |
title_short | HIV takes double hit before entry |
title_sort | hiv takes double hit before entry |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517473/ https://www.ncbi.nlm.nih.gov/pubmed/23216951 http://dx.doi.org/10.1186/1741-7007-10-99 |
work_keys_str_mv | AT sandersrogierw hivtakesdoublehitbeforeentry |